What is Leerink Partnrs’ Estimate for RCKT FY2026 Earnings?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Research analysts at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of ($1.67) per share for the year, down from their prior forecast of ($1.66). The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

A number of other analysts have also commented on RCKT. Weiss Ratings reissued a “sell (e+)” rating on shares of Rocket Pharmaceuticals in a report on Wednesday, October 8th. Bank of America raised Rocket Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $4.00 to $10.00 in a report on Wednesday, August 20th. Leerink Partners decreased their price objective on Rocket Pharmaceuticals from $9.00 to $7.00 and set a “market perform” rating for the company in a report on Friday, October 3rd. Cantor Fitzgerald decreased their price objective on Rocket Pharmaceuticals from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, August 8th. Finally, Chardan Capital reissued a “buy” rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rocket Pharmaceuticals presently has an average rating of “Hold” and an average target price of $16.67.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT opened at $3.71 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.39 and a current ratio of 6.39. The stock has a 50 day moving average price of $3.31 and a two-hundred day moving average price of $4.05. The firm has a market capitalization of $400.31 million, a P/E ratio of -1.48 and a beta of 0.60. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $18.89.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). During the same quarter last year, the company earned ($0.74) earnings per share.

Insiders Place Their Bets

In other news, insider Jonathan David Schwartz sold 11,161 shares of the business’s stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $3.02, for a total value of $33,706.22. Following the transaction, the insider owned 224,094 shares in the company, valued at $676,763.88. The trade was a 4.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Militello sold 28,918 shares of the business’s stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $3.96, for a total value of $114,515.28. Following the completion of the transaction, the insider owned 67,006 shares in the company, valued at $265,343.76. The trade was a 30.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,368 shares of company stock worth $221,675 over the last 90 days. 24.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. grew its holdings in Rocket Pharmaceuticals by 16.1% during the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,658 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Rocket Pharmaceuticals by 8.4% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 21,885 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 1,689 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Rocket Pharmaceuticals by 10.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 21,388 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 2,059 shares during the period. HighTower Advisors LLC grew its holdings in Rocket Pharmaceuticals by 16.6% during the first quarter. HighTower Advisors LLC now owns 20,700 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,952 shares during the period. Finally, Arizona State Retirement System grew its holdings in Rocket Pharmaceuticals by 15.3% during the first quarter. Arizona State Retirement System now owns 22,852 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 3,026 shares during the period. 98.39% of the stock is owned by institutional investors.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.